|
Points to consider
|
Benefits of SLNs over liposomes
|
Benefits of SLNs over polymeric Nano-systems
|
| Organ Distribution |
SLNs High bioactivity is in the spleen while Liposomes are more active in the liver due to the flexibility difference of both formulations.
22
|
SLNs do not have undesirable effects unlike polymeric nanoparticles such as accumulation in various organs like the spleen, liver, etc. which leads to unwanted effects.
23
|
| Flexibility in the selection of preparation method |
The use of organic solvents can be avoided by the selection of a suitable method with scale-up and reproducible properties. |
Homogenization is an aqueous-based scalable method available for the production of SLNs.
24
|
| Target ability |
Both Surfaces modified liposomes and SLNs can be used for site-specific delivery but very less work is reported on gene delivery with liposomes due to various cellular barriers like the liposome-cargo-barrier interaction, binding of the liposome to the cell surface, liposome entry into the cells by endocytosis, or direct traversing of the plasma membrane, escape of the liposome from the endosome and dissociation of the liposome to release the nucleic acid payload.
25
|
Surface modified SLNs offer site-specific delivery for the drugs as well as protein, DNA, and RNA while polymeric nanoparticles may produce nonspecific drug delivery and still more work is to be done on a tailored synthetic approach for gene delivery.
26
|
